Ellodi Pharmaceuticals is a specialty pharmaceutical company that focuses on advancing treatments for Eosinophilic Esophagitis (EoE), a rare and chronic allergic inflammatory condition that currently has no FDA-approved first-line treatment. The company's main objective is to develop and commercialize innovative therapies for gastrointestinal disorders and rare diseases, with a particular focus on EoE. Ellodi Pharmaceuticals' seasoned team is dedicated to the clinical development of APT-1011, a novel therapy currently in Phase 3 development for the treatment of EoE. By prioritizing patients and caregivers, Ellodi Pharmaceuticals aims to improve and transform the lives of those affected by EoE.